Silobreaker.com
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Sunday, November 22, 2009 12:26 AM

Published 11/02/2009 by News-Medical.Net


BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients

Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients.

The poster included data on 56 patients in...

Share this 

What others report on the same story

Market Report -- In Play (ZGEN)
ZymoGenetics and Bristol-Myers Squibb present final Ph. 1b results for PEG-Interferon lambda in hepatitis C Co and Bristol-Myers Squibb (BMY) present final results ... - [11/02/2009 - Briefing.com via MSN Money]
ZymoGenetics (ZGEN) and Bristol-Myers (BMY) Pre... - [11/02/2009 - Street Insider]
1
Network

Blogs

sort by: Date | Relevance
Antiviral cocktail shows promise against resist... [H5N1 - 10/28/2009]
Via Medical News Today.com: Triple-combo Drug Shows Promise Against Antiviral Resistant H1N1. Excerpt:An experimental drug cocktail that includes three prescriptions ...
1

  •  
  •  
  •